Kite Pharma Announces FDA Orphan Drug Designations for KTE-C19 in Five Additional Indications
May 02, 2016 16:05 ET
|
Kite Pharma, Inc.
All Hematological Malignancies Targeted by KTE-C19 Development Now Covered by Orphan Drug Designations in U.S. and EU SANTA MONICA, Calif., May 02, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc....
Kite Pharma Announces Presentations at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
April 28, 2016 07:00 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE) ("Kite") a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell...
Kite Pharma Presents Updated Phase 1 Results from ZUMA-1 at the American Association of Cancer Research (AACR) Annual Meeting
April 19, 2016 16:05 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., April 19, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) ("Kite") today announced updated clinical results from the phase 1 portion of Kite's ZUMA-1 trial of its lead...
Kite Pharma Commends Scientific Advisory Board Members on Awards Received from the American Association of Cancer Research (AACR)
April 18, 2016 16:05 ET
|
Kite Pharma, Inc.
Antoni Ribas, M.D., Ph.D. and Ronald Levy, M.D. recognized for their major contributions to cancer research SANTA MONICA, Calif., April 18, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc....
Kite Pharma Announces Review of National Cancer Institute’s Manufacturing Facilities
April 16, 2016 14:15 ET
|
Kite Pharma, Inc.
- Kite’s four ongoing multi-center clinical trials of its lead product candidate, KTE-C19, are continuing - - Kite remains on track to file an investigational new drug application (IND) with the Food...
Kite Pharma Announces Key Presentations on KTE-C19 and Engineered Cell Therapy Pipeline Programs at the Annual Meeting of the American Association for Cancer Research (AACR)
April 15, 2016 20:06 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., April 15, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE) ("Kite") a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell...
Kite Pharma Announces Clinical Collaboration to Evaluate Two Novel Immunotherapies for Patients with Non-Hodgkin Lymphoma
March 17, 2016 08:00 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., March 17, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today announced that it has entered into a clinical trial collaboration with Genentech, a member of the Roche...
Kite Pharma Announces Clinical and Manufacturing Updates on KTE-C19 and MAGE-A3 Product Candidates at the Annual Meeting of the American Association for Cancer Research (AACR)
March 16, 2016 16:54 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., March 16, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE) (“Kite”) a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell...
Kite Pharma Deepens Cell Manufacturing and Operations Expertise with Appointment of Tim Moore
March 16, 2016 07:30 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., March 16, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today announced the appointment of Tim Moore as Executive Vice President, Technical Operations. With more...
Kite Pharma to Present at March 2016 Investor Conferences
March 03, 2016 16:55 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., March 03, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE) today announced that management will present at two investor conferences in March:Cowen and Company...